Tirzepatide Peptide
For twenty years GIP was the incretin receptor nobody wanted, written off as the one that was not earning its place in the system. Tirzepatide was built to pull it on purpose, and the field had to go back and re-read its own literature.
Choose your pack
For research use only. Not for human or veterinary use.
What Tirzepatide Peptide is
The plain-language version, first.
Everybody knew GIP was the useless one. Nobody actually checked.
Tirzepatide is a 39-amino-acid synthetic peptide that binds both the GIP and GLP-1 receptors. It carries the Lilly development code LY3298176 and is an approved prescription medicine in Canada and the United States.
Somebody told you once you can't swim for thirty minutes after eating. Everybody knew it.
Your mom knew it. The lifeguard knew it. There was a poster.
Nobody ever checked.
Incretin research had one of those, and it ran for twenty years.
There are two incretin receptors. GLP-1 got the attention, the funding, and every molecule anybody bothered to build. GIP got a shrug.
The read was that GIP wasn't earning its spot, and for a good stretch the serious position was that you'd want to block it. Not use it. Block it.
Then somebody built a molecule that grabs both anyway, and twenty years ended the way these things usually end. Somebody just tried it.
The build is a GIP backbone with the residues tuned so it holds onto both receptors. Two Aib swaps so your enzymes can't get a grip on it.
And a twenty-carbon fatty tail that hangs onto albumin like a guy gripping a bus pole, which is the only reason this is a weekly molecule and not an hourly one.
It also answers to LY3298176, which is the name it had back when it was a row in a spreadsheet.
What is tirzepatide?
Mechanism studied, not outcome promised.
The 39 residue backbone is a GIP sequence engineered to activate the GLP-1 receptor as well, not the other way round.
Aminoisobutyric acid at positions 2 and 13 blocks DPP-4 cleavage. A C20 fatty diacid on lysine 20 binds albumin for once weekly dosing.
The receptor the whole field had been using as a coaster.
Look. You've got a remote in a drawer somewhere you've been using as a coaster for years, because you assumed it didn't work.
That's GIP.
Two incretin receptors, both sitting in the same system the entire time, one of them broadly written off. One molecule now holds both down.
Nobody discovered a new receptor here. They just stopped being wrong about an old one.
And that's the part worth sitting with for a second. The interesting thing isn't that two is more than one.
It's that the second one was the one everybody had already crossed off. Building a molecule to grab it on purpose was a bet against the whole room.
Here's the honest part. Binding and signalling potency are measurable, published, and boring in the good way.
What all of it adds up to inside an actual person is a clinical question. It has been asked properly, and those answers live in journals, not on a page trying to sell you powder.
We'll point at the file. We're not going to read it to you and call that a summary.
The research so far for Tirzepatide Peptide
Where the evidence is thin, we say so.
Regulatory approval in Canada and the United States. Published receptor pharmacology at both targets, pharmacokinetics, half-life, and a phase 3 programme with a safety record collected under observation.
Any basis for us to describe outcomes to you. Approval is granted to a prescription product under medical supervision, which is not what is being sold here.
Strip out the dual-agonist framing and what is left is a field revising a twenty-year position on a single receptor. That revision, not the molecule count, is what makes this programme worth reading.
The only thing on this shelf with a regulator's signature on it.
Alright, this one breaks our routine, and we'd rather say so than play it cool.
Most of what sits on these shelves is animal data with a forum thread on top of it. That's just true.
Tirzepatide is an approved prescription medicine in Canada and the US, with a published file running from receptor pharmacology the whole way through phase 3.
Out of everything here, it's the only one a regulator has actually signed.
What that file nails down: binding at both receptors, the pharmacokinetics, the roughly five-day half-life, and how the ramp changes what people tolerate.
What we're not doing is quoting you endpoint numbers. Those belong in the papers, read whole, not chopped up by a vendor until they start sounding like a promise.
Approved, thoroughly documented, and still not ours to make claims about. All three at once.
Have a look at the vial sizes we currently have in stock.
Tirzepatide Peptide specs
The chemistry, exactly as released.
Who studies Tirzepatide Peptide
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Incretin pharmacology
The cleanest available test of what GIP receptor engagement contributes when GLP-1 signalling is already covered, with published potency data at both targets.
Peptide chemistry
A worked example of half-life engineering: Aib substitutions at positions 2 and 13 against enzymatic cleavage, and a twenty-carbon fatty diacid for albumin binding.
Trial design
One of the largest published programmes in peptide pharmacology, including a head-to-head against another molecule in the same class, which is rare and expensive to run.
Regulatory affairs
An approved prescription medicine in two jurisdictions, which makes its filing history a reference case for anything that follows it through the same path.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
Tirzepatide Peptide backstory
How it got here.
The good part of this molecule's history isn't a discovery. It's an argument.
Two incretin receptors, both spotted decades ago. GLP-1 got the attention and every drug programme going.
GIP got written off. Its signal looked flat in exactly the group everybody cared about, so the whole thing read like a dead end.
And a serious pile of work argued the move was to block the receptor. Not engage it. Block it.
That held for twenty years. It was wrong. And it got corrected by somebody ignoring the consensus and building the thing anyway.
The chemistry is the same trick running through this entire shelf. Swapped residues so enzymes can't cut it, and a fatty tail that grabs albumin so the thing lasts a week instead of an afternoon.
Filed as LY3298176. Approved in two countries. Still the only molecule here with a regulator's name on it.
- 1
Two receptors, one favourite
GLP-1 and GIP were both identified as incretin receptors decades ago. GLP-1 got the programmes and the molecules. GIP got a reputation.
- 2
The twenty-year wrong turn
GIP signalling looked blunted in the group under study, so the field largely wrote it off, and a serious line of work argued for blocking the receptor instead of engaging it.
- 3
Built anyway
Rather than settle the argument on paper, the programme built a molecule on a GIP backbone that engages both receptors, and filed it as LY3298176.
- 4
Where it stands
Approved in Canada and the United States as a prescription medicine. The largest published programme of anything in this catalogue, and the only approval on the shelf.
Buying Tirzepatide Peptide in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
Same day out of British Columbia
Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.
Then into the fridge
Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.
Complex synthesis, high demand
A 39 residue peptide with a lipid chain is a harder build than a short fragment, and demand in this class is enormous. That combination is exactly what produces vials that are not what the label says.
Tirzepatide Peptide vs Semaglutide
Stacked together constantly, compared almost never.
This is the comparison the field actually cares about, and for once the internet is asking the right question.
Tirzepatide engages two incretin receptors, GIP and GLP-1, on a GIP backbone. The GIP arm is the contested one, and adding it deliberately was a bet against twenty years of consensus.
Semaglutide engages the GLP-1 receptor only, built on human GLP-1(7-37) with a C18 diacid for albumin binding.
One receptor against two, from the same era of chemistry. Both have public programmes you can read directly, and reading them beats taking our word for anything. Semaglutide has its own page here
Stuff people ask about Tirzepatide Peptide
If your question is not here, email us. Real human answers.
A 39-amino-acid synthetic peptide, Lilly development code LY3298176, that binds both the GIP and GLP-1 incretin receptors. It is built on a GIP peptide backbone with Aib substitutions at positions 2 and 13, and carries a twenty-carbon fatty diacid that binds albumin and extends its half-life to roughly five days.
Because GIP was the contested receptor. For roughly two decades the field questioned whether engaging it was useful at all, and a serious line of work argued for blocking it instead. Building the backbone around GIP was a deliberate bet against that reading, and it is the single most interesting design decision in the molecule.
Semaglutide engages the GLP-1 receptor. Tirzepatide engages GLP-1 and GIP. One extra receptor, and it happens to be the one the field had spent twenty years arguing about. Both have published programmes you can read directly.
Yes. It is an approved prescription medicine in Canada and the United States, which makes it the only compound on this shelf with a regulatory approval behind it. That approval covers a prescription product used under medical supervision, and it does not extend to research material bought online.
That is the development code it was filed under, and a lot of the published literature still uses it. If you are reading journals rather than forums, that is the name you will keep running into.
Prohibited. Metabolic modulators of this class sit on the WADA prohibited list, in and out of competition. If you are subject to testing, this is not a grey area.
No. Canada only. Cold-chain across one country is a promise we can keep. Across six it is a hope.
Good pairing options with Tirzepatide Peptide
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as Tirzepatide Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
The original incretin, exactly as your gut makes it, no edits. Plasma half-life about one minute, which is why every famous analogue exists and why this one is strictly a reference material.
Two different satiety signalling systems in one vial. Which sounds simple until you try to work out which half any given result belongs to.
Order Tirzepatide Peptide right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching Tirzepatide Peptide and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 19, 2026
People also search for Tirzepatide Peptide
Other names for the same compound.